<DOC>
	<DOCNO>NCT03058471</DOCNO>
	<brief_summary>This single center , prospective , randomize control open label trial one side cross design compare efficacy initiate Methotrexate ( Mtx ) early post Chikungunya induce arthritis ( 4-12 week onset ) Non Steroidal Anti inflammatory Drugs ( NSAID ) alone .</brief_summary>
	<brief_title>Efficacy Starting Methotrexate Early Chikungunya Arthritis</brief_title>
	<detailed_description>This single center , prospective , randomize control open label trial cross design . Patients recruit outpatient department internal medicine rheumatology clinic Post Graduate Institute Medical Education Research ( PGIMER ) , Chandigarh , India , tertiary care hospital . . Inclusion Criteria 1 . Patients confirm Chikungunya virus infection per World Health Organisation ( WHO ) guideline define atleast one follow 1 . Presence viral ribonucleic acid serum determine Real Time Polymerase Chain Reaction ( RT PCR ) acute phase &lt; 7 day fever 2 . Presence virus specific IgM antibody serum 2 . Persistent arthritis 4 week onset fever duration le 12 week ( early post viral arthritis ) 3 . Age 16 year 4 . Patients willing give inform consent Exclusion Criteria : 1 . Patients mixed infection i.e . dengue . 2 . Having know rheumatological disease currently take treatment 3 . Pregnant breastfeed woman 4 . Any contraindication methotrexate ( Mtx ) The clinical detail patient record proforma include detail regard fever musculoskeletal symptom . At baseline , complete blood count ( CBC ) , erythrocyte sedimentation rate ( ESR ) , C-Reactive protein ( CRP ) , liver function test ( LFT ) , Renal Function Test ( RFT ) , rheumatoid factor ( RF ) , anti- citrullinated peptide antibody ( ACPA ) do . All eligible patient randomize two group . Randomization do computer generate block randomization block four six . In one group methotrexate start dose 10 mg/week check basal CBC , LFT RFT increase gradually ( 5mg/each visit ) 25 mg response subsequent visit group continue NSAID.If remission ( swollen tender joint visit ) achieve NSAID group 2 month give MTX .MTX group give NSAID need basis record visit . Both group give depot methyl prednisolone 80 mg ,2 dose 1 week apart 5 swollen tender joint visit.The patient assess 0,1 , 2,4 6 month Tender Joint Count ( TJC ) , Swollen joint count ( SJC ) Indian Health Assessment Questionnaire ( HAQ ) . If patient achieves remission methotrexate group , last dose methotrexate continue till next visit . The dose halve next visit stop next.In NSAID group , remission achieve , dose change need basis patient relapse start methotrexate . Allocation concealment ensure mean enclose randomization sequence seal opaque envelope . One investigator , blind treatment received subject , assess subject recruitment study subsequently next visit end study period . Primary efficacy end point proportion patient achieve remission ( No tender swell joint ) 6 month . Secondary end point time duration achieve remission , change DAS28 ESR/CRP score , proportion patient achieve remission simplify disease activity index ( SDAI ) clinical disease activity index ( CDAI ) score , functional status assess Health Assessment Questionnaire-Indian version ( HAQ ) , change pain VAS ( Visual Analogue Scale ) 100mm , adverse effect difference NSAID intra muscular steroid injection requirement among group .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Chikungunya Fever</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>1 . Patients confirm CHIKV infection per WHO guideline define atleast one follow 1 . Presence viral ribonucleic acid serum determine RT PCR acute phase &lt; 7 day fever 2 . Presence virus specific IgM antibody serum 2 . Persistent arthritis 4 week onset fever duration le 12 week 3 . Age 16 year 4 . Patients willing give inform consent 1 . Patients mixed infection i.e . dengue . 2 . Having know rheumatological disease currently take treatment 3 . Pregnant breastfeed woman 4 . Any contraindication methotrexate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>